Descripción de la empresa
MediWound Ltd. operates as a biopharmaceutical entity dedicated to the development, manufacturing, and commercialization of novel bio-therapeutic and non-surgical solutions designed for tissue repair and regeneration. The company's operational scope extends across the United States, Germany, Italy, Spain, and international markets, with a primary focus on marketing the biopharmaceutical product NexoBrid. Within the broader financial landscape, MediWound is classified under the Healthcare sector and specifically functions within the Biotechnology industry, a domain characterized by high research intensity and significant capital requirements for product development. As of the latest reporting period, the company holds a market capitalization of $221.96M and generated annual revenue of $16.96M while maintaining an employee base of 121 individuals. These valuation and revenue figures indicate that MediWound functions as a mid-cap biotechnology firm, suggesting a position where the market values the company based on future potential and intellectual property rather than established cash flow generation, typical for companies in the early-to-mid stages of commercialization within the biotech sector.
Salud financiera
The financial performance of MediWound Ltd. is defined by a revenue stream of $16.96M for the trailing twelve months, which contrasts sharply with a net income loss of $-23,879,000 and an EBITDA of $-24,280,000. The substantial gap between the positive revenue of $16.96M and the significant negative net income reveals a cost structure where operating expenses far exceed gross profit, a common characteristic in biotechnology firms scaling their commercial operations. The company generated a free cash flow of $-15,578,875, indicating that capital expenditures and working capital requirements have consumed cash reserves, thereby limiting immediate financial flexibility for discretionary spending or large-scale acquisitions. Profitability metrics further illustrate this pressure, with a gross margin of 19.2%, an operating margin of -417.8%, and a profit margin of -140.8%. The negative operating and profit margins demonstrate that for every dollar of revenue generated, the company incurs more than one dollar in operating and total costs, respectively, highlighting the heavy burden of research, development, and sales expenditures. In terms of leverage, the company holds $53.14M in cash against $8.78M in debt, supported by a debt-to-equity ratio of 20.11, which suggests a balance sheet that is conservatively structured with cash significantly outweighing liabilities despite the high leverage ratio metric. Liquidity is further supported by a current ratio of 2.33, indicating that the company possesses more than double the current assets necessary to cover its short-term obligations without immediate distress. Return metrics show a return on equity of -63.9% and a return on assets of -19.8%, which reveal that management effectiveness in generating shareholder value and utilizing asset base has been negative, a standard metric for growth-stage biotech companies prioritizing reinvestment over profit distribution.
Evaluación de valoración
Valuation multiples for MediWound reflect its status as a company with negative earnings, evidenced by a trailing P/E ratio that is not available and a forward P/E of -7.96. The difference between these metrics, specifically the negative forward P/E, implies that the market is pricing the stock based on expectations of future earnings turnaround rather than current profitability performance. Asset-based valuation is represented by a price-to-book ratio of 5.08, indicating that the market values the company at a significant premium over its net book value, reflecting confidence in the value of its intellectual property and pipeline potential. Alternative valuation metrics provide additional context, with a price-to-sales ratio of 13.09 and an EV/EBITDA of -7.31, suggesting that investors are willing to pay a high multiple for every dollar of sales generated. Price action over the last year shows a 52-week high of $22.50 and a 52-week low of $14.77, with the current trading price situated below the high, reflecting the volatility typical of small-cap biotechnology stocks. The stock exhibits a beta of 0.15, which indicates that the share price is significantly less volatile than the broader market, moving with much lower sensitivity to general market fluctuations compared to large-cap equities.
Growth & Income
The growth profile of MediWound Ltd. is characterized by a revenue growth rate of -68.0% year-over-year, while earnings growth is marked as N/A due to the absence of profitable earnings in the prior period. The contraction in revenue suggests a challenging commercial environment or product cycle adjustments, and since there are no earnings to compare, the implication is that the company is in a phase of scaling down or stabilizing sales rather than expanding them. Regarding income distribution, the company does not pay dividends, evidenced by a dividend yield of N/A and a payout ratio of 0.0%. This lack of dividend payment is typical for biotechnology firms that reinvest all available capital, including operating cash flows, back into research, development, and commercialization efforts rather than distributing income to shareholders. Consequently, the overall growth and income profile for MediWound is one of negative revenue expansion with no current income generation, relying entirely on existing cash reserves to fund operations until the company achieves profitability or secures external financing.